The integration of BRCA testing into oncology clinics

British Journal of Nursing - Tập 25 Số 12 - Trang 690-694 - 2016
Natalie Percival1, Angela George2, Jennifer Gyertson3, Monica Hamill3, Andreia Fernandes4, Emily Davies4, Nazneen Rahman5, Susana Banerjee6
1Advanced Nurse Practitioner, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
2Consultant Oncogenetics, Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Division of Genetics and Epidemiology, The Institute of Cancer Research, London
3Research Nurse, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
4Clinical Nurse Specialist, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
5Professor of Genetics, The Royal Marsden NHS Foundation Trust and Division of Genetics and Epidemiology, The Institute of Cancer Research, London
6Consultant Medical Oncologist, Gynaecology Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London

Tóm tắt

Purpose: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used. The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model. Methods: Nurses undertook generic consent training and specific counselling training for BRCA testing in the form of a series of online videos, written materials and checklists before obtaining approval to consent patients for germline BRCA1 and BRCA2 mutations. Results: Between July 2013 and December 2015, 108 women with ovarian cancer were counselled and consented by nurses in the medical oncology clinics at a single centre (The Royal Marsden, UK). This represented 36% of all ovarian cancer patients offered BRCA testing in the oncology clinics at the centre. Feedback from patients and nurses was encouraging with no significant issues raised in the counselling and consenting process. Conclusion: The mainstreaming model allows for greater access to BRCA testing for ovarian cancer patients, many of whom may benefit from personalised therapy (PARP inhibitors). This is the first report of oncology nurses in the BRCA testing pathway. Specialist oncology nurses trained in BRCA testing have an important role within a multidisciplinary team counselling and consenting patients to undergo BRCA testing.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2011.39.8545

10.1038/nrclinonc.2010.116

10.1111/jocn.12675

10.1038/bjc.2015.396

10.12968/bjon.2016.25.1.8

10.1097/01.NPR.0000471359.56745.e4

10.1016/S1470-2045(14)70228-1

10.1093/annonc/mdw142

10.7861/clinmedicine.14-4-436

10.1186/s13073-015-0128-4

Thông tin
Thông tin xuất bản

British Journal of Nursing

Tập 25 Số 12

690-694

Thông tin tác giả